Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 4, 1997, Pages 404-406

  Northoff, G ^a,b   Eckert, J ^a   Fritze, J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Amantadine; Catatonia; Glutamate; NMDA antagonist

Indexed keywords

AMANTADINE; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CASE REPORT; CATATONIA; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE;

EID: 0030954175     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.4.404     Document Type: Article

References (17)

1. Gelenberg AJ. The catatonic syndrome. Lancet 1976;i:1339-41.
2. Taylor MA. Catatonia: a review of the behavioral neurologic syndrome. Neuropsychiatry, Neuropsychology and Behavioral Neurology 1990;3:48-72.
3. Northoff G, Demisch L, Wenke J, Pflug B. Plasma homovanillic acid concentration in catatonia. Biol Psychiatry 1996;39:436-43.
4. Starkstein S, Petracca G, Teson A, Chemerinski E, Merello M, Migliorelli R, Leiguardia R. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry 1996;60:326-32.
5. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neurol Transm Park Dis Dement Sect 1993;6:63-72.
6. Greenamyre T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-69.
7. Tsai G, Passani L, Slusher B, Carter R, Baer L, Kleinman J, Coyle J. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52:829-36.
8. Rosebush P, Furlong B, Mazurek M. Catatonic syndrome in a general psychiatric population: frequency, clinical presentation and response to lorazepam. J Clin Psychiatry 1990;9:357-62.
9. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970;212(suppl):11-9.
10. Guy W, ed. ECDEU assessment manual for psychopharmacology. Washington, DC: ECDEU 1976;534-7.
11. Lund CE, Mortimer AM, Rogers D. Motor, volitional and behavioral disorders in schizophrenia. Br J Psychiatry 1991;158:323-7.
12. Endicott J, Spitzer R, Flies J, et al. The global assessment scale. Arch Gen Psychiatry 1976;33:766-71.
13. American Psychiatric Association. Diagnostic manual. 4th ed. Washington DC: APA, 1994.
14. Goff DC, Tsai G, Manoach D, Coyle J. Dose-finding of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-5.
15. Hietala I, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1.
16. Benes F, Vincent S, Alsterberg G, Bird E, Giovanni J. Increased GABA-A receptor binding in superficial layers of cingulate cortex in schizophrenia. J Neurosci 1992; 12:924-9.
17. Eastwood SL, Porter R, Bumet P, Kerwin R, Harrison P. Non-NMDA-glutamate receptor expression in schizophrenia. Schizophr Res 1996;18:174.